期刊文献+

Ⅲ型干扰素信号通路诱导肺癌细胞凋亡的机制研究 被引量:2

Research on mechanism of IFN λ-induced apoptosis in human lung cancer cells
下载PDF
导出
摘要 目的研究半胱氨酸蛋白酶(Caspase)激活方式,探讨Ⅲ型干扰素(IFNλ)信号通路诱导凋亡的机制。方法用IFNλ刺激人肺癌细胞A549,或用IL-10刺激表达复合受体FL-10R1/λR1的A549/FL-10R1/λR1细胞。用流式细胞分析检测Caspase3、Caspase8和Caspase9的激活程度。用Caspase抑制剂Z-VAD-FMK抑制Caspase,用流式细胞分析检测Caspase的激活情况,并通过末端转移酶标记术观察其对细胞凋亡的影响。结果 IFNλ信号通路可以上调Caspase3、Caspase8和Caspase9活化水平(5.5、3.5和4.5倍)并诱导凋亡。Z-VAD-FMK抑制Caspase3和Caspase8激活(60.0%和57.9%),但是提高了Caspase9的激活水平(35.1%),且不能阻止凋亡。结论 IFNλ信号可以激活不同的Caspase,通过激活死亡受体通路和线粒体通路来诱导凋亡,但是Caspase不是IFNλ诱导凋亡所必需的。 Objective To investigate the activation pattern of caspases by type Ⅲ interferon (IFNS) in apoptosis induction. Methods IFN λ stimulated lung cancer cell line A549 or IL-10 stimulated A549/FL-10R1/λR1, respectively. And the activation of caspase 3, caspase 8 and caspase 9 was determined by flow cytometry. Pancaspase inhibitor Z-VAD-FMK was used to inhibit caspase activation, and activated caspase levels were tested by flow cytometry. The level of apoptosis was tested by counting viable cells, Results IFN λ, signaling could activate caspase 3, caspase 8 and caspase 9 by 5.5, 3.5 and 4.5 times, respectively, and induce apoptosis. Z-VAD-FMK inhibited the activation of caspase 3 and caspase 8 by 60.0% and 57.9%, respectively, but activated caspase 9 by 35.1%. h could not stop apoptosis induced by IFNλ signaling. Conclusion IFNλ signaling activates various caspases, and induces both death receptor-mediated and mitochondria--mediated apoptotic pathways, which lead to apoptosis. But caspases are not necessary to this apoptosis induction.
出处 《北京医学》 CAS 2011年第12期989-992,共4页 Beijing Medical Journal
基金 艾滋病研究北京市重点实验室项目(BZ0089) 北京市属高等学校人才强教计划资助项目(PHR201007112)
关键词 Ⅲ型干扰素 半胱氨酸蛋白酶 凋亡 肺癌 复合受体 Ⅲ interferon(IFNh) Caspase Apoptosis Lung cancer Chimeric receptor
  • 相关文献

参考文献13

  • 1Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol,2008,19:311-318.
  • 2Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class Ⅱ cytokine receptor IL-28R. Nat Immunol,2003,4:63-68.
  • 3Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II eytokine receptor complex. Nat Immunol,2003,4:69-77.
  • 4Kelly C, Klenerrnan P, Barnes E. Interferon lambdas: the next cytokine storm. Gut,2011,60:1284-1293.
  • 5Kotenko SV, Izotova LS, Pollack BP, et al. interaction between the components of the interferon gamma receptor complex. J Biol Chem, 1995,270:20915-20921.
  • 6Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol,2011,26:213-219.
  • 7Mihic LL, Bulat V, Situm M, et al. The role of apoptosis in the pathogenesis of malignant melanoma. Coil Antropol,2010,34: 303-306.
  • 8Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferatire activity of IL-29/interferon-lambda 1: similarities with type 1 interferon signaling. J Biol Chem,2004,279:32269-32274.
  • 9Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic. IL-28A expression. Am J Physiol Gastrointest Liver Physiol,2005,289:G960-968.
  • 10Meager A, Visvalingam K, Dilger P, et al. Biological activity of interleukins-28 and -29: comparison with type 1 interferons. Cytokine,2005, 31:109-118.

同被引文献17

  • 1Pisick E, Jagadeesh S, Salgia R, et al. Receptor tyrosine kinases and inhibitors in lung cancer[J]. Sci World J, 2009, 6:589-604.
  • 2Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer[J]. Science, 1997, 275:1943-1947.
  • 3Steelman LS, Bertrrand FE, McCubrey JA, et al. The complexity of PTEN: mutation, marker and potential target for therapeutic inter- vention[J]. Expert Opin Ther Targets, 2004, 8:537-550.
  • 4Sabatini DM. roTOR and cancer: insights into a complex relation- ship[J]. Nat Rev Can, 2006, 6:729-734.
  • 5Shaw R J, Cantley LC. Ras PI (3)K and roTOR signalling controls tumour cell growth[J]. Nature, 2006, 441:424-430.
  • 6Massion PP, Tafian PM, Shyr Y, et al. Early involvement of the phosphatidylinositol 3-kinase /Akt pathway in lung cancer pro- gression[J]. Am J Respir Crit Care Med, 2004, 170:1088-1094.
  • 7Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K sig- naling[J]. Clin Cancer Res, 2006, 12:710-717.
  • 8Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal sur- vival by the serine-threonine protein kinase Akt [J]. Science, 1997, 275:661-665.
  • 9Tamura M, Gu I, Takino T, et al. Tumor suppressor PTEN inhibi- tion of cell invision, migration, and growth: differential involve- ment of focal adhesion kinase and pl30cas [J]. Cancer Res, 2008, 59:442-449.
  • 10Lira WT, Zhang WH, Miller CR, et al. PTEN and phosphorylated AKT expression and prognosis in early-and late-stage non-small cell lung cancer[J]. Oncology Rep, 2007, 17:853-857.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部